tolvaptan has been researched along with rifampin in 4 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (rifampin) | Trials (rifampin) | Recent Studies (post-2010) (rifampin) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 20,468 | 1,499 | 6,552 |
| Protein | Taxonomy | tolvaptan (IC50) | rifampin (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.949 | |
| Caspase-1 | Homo sapiens (human) | 8.319 | |
| Alpha-synuclein | Homo sapiens (human) | 7.1 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 0.03 | |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | 0.01 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bricmont, P; Mallikaarjun, S; Shoaf, SE | 1 |
| Behr, J; Dietrich, JW; Heyer, CM; Knoop, H; Knoop, U; Kuert, S; Roggenland, D; Suermann, M | 1 |
1 review(s) available for tolvaptan and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for tolvaptan and rifampin
| Article | Year |
|---|---|
Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Topics: 14-alpha Demethylase Inhibitors; Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Area Under Curve; Benzazepines; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Tolvaptan; Urination; Young Adult | 2012 |
2 other study(ies) available for tolvaptan and rifampin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Syndrome of inadequate antidiuretic hormone secretion in pulmonary tuberculosis - a therapeutic challenge.
Topics: Antibiotics, Antitubercular; Benzazepines; Combined Modality Therapy; Diet, Sodium-Restricted; Drug Interactions; Female; Fluid Therapy; Humans; Inappropriate ADH Syndrome; Middle Aged; Rifampin; Syndrome; Tolvaptan; Treatment Failure; Tuberculosis, Pulmonary | 2013 |